3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Stem Cell Transplant Complications
1
Neutropenia
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Interventions
pegfilgrastim
13
Filgrastim
13
Cytarabine
5
Cyclophosphamide
5
pegylated granulocyte colony-stimulating factor
4
Etoposide
4
Methotrexate
3
Doxorubicin
3
Docetaxel
3
trifluridine tipiracil drug combination
2
Vincristine
2
Daunorubicin
2
Cisplatin
2
Amifostine
2
trilaciclib
1
niraparib
1
lintuzumab
1
leridistim
1
isavuconazole
1
fludarabine phosphate
1
fish oil triglycerides
1
etoposide phosphate
1
eravacycline
1
eflapegrastim
1
angiotensin I (1-7)
1
Voriconazole
1
Vegetables
1
Topotecan
1
Thioguanine
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neutropenia
×
Levofloxacin
×
Clear all
NCT07528417
2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2
Not yet recruiting
75 enrolled